This report summarises what Blossom’s database shows about psychedelics and the peripartum period, and it is an unusual entry in this collection, because here the headline story is not really about psychedelics. Postpartum depression already has approved fast-acting drugs, they are neurosteroids rather than psychedelics, classic psychedelics are largely shut out by pregnancy and breastfeeding safety, and the genuine psychedelic-adjacent research, mostly perioperative ketamine, is promising but mixed. It is a field where psychedelics are a secondary, constrained and still-early player.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Peripartum mental illness is serious, postpartum psychosis is a medical emergency, and suicide is a leading cause of maternal death; if you are struggling, please seek help urgently. Crucially, no classic psychedelic is approved or recommended for any peripartum condition, and using one during pregnancy or breastfeeding is specifically unsafe: the risks to a developing baby or nursing infant are unknown, and being incapacitated while caring for a newborn is dangerous in itself. Effective, approved treatments for postpartum depression now exist, and they, with proper medical guidance, are where help should begin.
A word on scope and numbers. The trial count under this topic looks healthy, but it is dominated by studies of perioperative ketamine and esketamine, and of the approved neurosteroids, rather than by classic-psychedelic therapy. The genuinely psychedelic, postpartum-specific clinical evidence is tiny, effectively one small open-label study of a short-acting compound. Read the counts with that composition in mind.
The race that psychedelics did not win
In most of this field, the compelling pitch for psychedelics is speed: a single treatment that lifts depression in days rather than weeks, for people the slow conventional drugs have failed. Postpartum depression is the one place where that pitch has already been answered, by something else. Brexanolone, an intravenous neurosteroid, was approved in 2019 as the first drug specifically for postpartum depression, and in 2023 zuranolone became the first oral one, a short course that can work within days. Neither is a psychedelic; both act on the brain’s GABA system and reflect a distinct line of science about the hormone-derived neurosteroids that fall sharply after birth.
This changes the frame for everything that follows. A fast-acting antidepressant for this population is no longer a gap waiting to be filled; it is a treatment that exists, against which any newcomer must compete. Reviews that weigh psychedelics for postpartum depression do so explicitly in this light[1]Ther Adv Psychopharmacol, psychedelic therapy and postpartum depression: priorities and prospects (2026), positioning them as a possible future option for people the approved treatments do not reach, not as the obvious next breakthrough. It is a healthy reminder that psychedelics are one promising approach among several, not the only road to rapid relief.
Why classic psychedelics are mostly shut out
The second defining fact is a safety wall. Pregnancy and breastfeeding are among the firmest exclusion criteria in all of psychedelic research, for reasons that are not bureaucratic. The effects of psilocybin, MDMA or LSD on a developing fetus are essentially unstudied and potentially serious; the drugs can pass into breast milk; and, beyond the pharmacology, there is the plain practical danger of a parent being profoundly altered and incapacitated for many hours while solely responsible for a newborn. A 2025 preclinical study added a direct note of caution, reporting that psilocybin given during the postpartum period produced lasting anxiety-like effects in mouse mothers and adverse effects in their offspring rather than benefit. These are not problems that better trial design can wave away. They mean that, for much of the peripartum period, classic psychedelics are effectively off the table.
This is why the psychedelic research that does exist clusters at the edges of the period, or uses very different tools. It also explains why the most creative recent thinking has gone not into testing standard psychedelics in pregnancy, which would be hard to justify, but into changing the drugs themselves to fit the constraint.
The real activity: perioperative ketamine
The largest body of genuinely relevant evidence concerns ketamine and its enantiomer esketamine, used in a specific preventive way: a single low dose given around caesarean delivery, when the woman is already in hospital, to head off postpartum depression. A 2022 meta-analysis of these perioperative trials found that a single ketamine dose reduced short-term postpartum depression symptoms[2]Psychiatry Research, perioperative ketamine for preventing PPD meta-analysis (2022), and more recent caesarean-section studies of low-dose esketamine report similar early benefits[3]single low-dose esketamine and PPD in caesarean women (2026). As a preventive delivered at an opportune moment, it is a genuinely sensible idea.
But the evidence is mixed and shallow. A careful 2017 randomised trial found no preventive effect from a single ketamine bolus[4]Arch Gynecol Obstet, single low-dose ketamine does not prevent PPD RCT (2017), the positive findings tend to be short-term, the trials are heterogeneous, and there are breastfeeding considerations whenever an anaesthetic-class drug is used around delivery. It is also worth being precise that this is prevention at the moment of birth, not treatment for a mother who becomes depressed weeks or months later, and that esketamine, despite the old page’s claim, is not approved for postpartum depression. The fair summary is a real, actively pursued preventive signal that has not yet been pinned down.
The clever idea, and a cautionary tale
The most interesting recent development confronts the duration problem directly. If the obstacle to using a psychedelic in a new parent is that it lasts hours, the answer might be one that lasts minutes. Inhaled 5-MeO-DMT, developed as GH001, produces a very short, very intense experience, and a Phase 2a study reported that all ten women with postpartum depression treated were in remission a week later[5]J Clin Psychiatry, inhaled 5-MeO-DMT (GH001) for PPD Phase 2a open-label (2026). On its face, a brief treatment producing complete remission is close to the ideal for this population.
The reasons for caution are instructive. The study had ten participants, no control group and no blinding, the precise conditions under which expectancy and natural recovery inflate apparent results, and a "100% remission" figure from such a design should be read as hypothesis-generating, not as proof. Most tellingly, the developer has since deprioritised its postpartum programme to concentrate on treatment-resistant depression, which is not what a company does with a confirmed breakthrough. A separate short-acting compound, RE104, remains at the early safety stage in healthy volunteers[6]J Clin Psychopharmacol, RE104 subcutaneous short-acting psychedelic Phase 1 (2025). The short-acting concept is genuinely well-matched to the problem and deserves proper, controlled trials; what it does not yet have is evidence.
Reading this honestly
So where does the peripartum period sit? It is the clearest case in this field of psychedelics being a secondary, constrained option rather than a leading one. The fast-acting treatment that psychedelics promise elsewhere has, for postpartum depression, already arrived in the form of neurosteroids; classic psychedelics are largely and rightly excluded during pregnancy and breastfeeding; the real psychedelic-adjacent evidence, perioperative ketamine, is promising but unsettled; and the most exciting psychedelic-specific result is a tiny open-label study from a programme its own sponsor has stepped back from. The thoughtful reviews treat this as an area of genuine but distinctly future-tense possibility[7]J Psychopharmacol, postpartum depression: a role for psychedelics? (2022). For new and expectant parents, the truthful and reassuring message is that effective, approved rapid treatments for postpartum depression now exist, that psychedelics are not currently among the safe or recommended options, and that any future role will have to be carved out carefully, within real limits, and only where the treatments that already work fall short.